The Aporia
Gonzalez, J. (2026, October 8). Alphabet’s biolab in funding talks at $40B valuation. Semafor. https://www.semafor.com/article/10/08/2026/alphabets-biolab-in-funding-talks-at-40b-valuation
Gonzalez, Jeronimo. “Alphabet’s biolab in funding talks at $40B valuation.” Semafor, 8 Oct. 2026, https://www.semafor.com/article/10/08/2026/alphabets-biolab-in-funding-talks-at-40b-valuation.
Gonzalez, Jeronimo. “Alphabet’s biolab in funding talks at $40B valuation.” Semafor, October 8, 2026. https://www.semafor.com/article/10/08/2026/alphabets-biolab-in-funding-talks-at-40b-valuation.
Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.
Alphabet's Isomorphic Labs, led by former Google DeepMind CEO and Nobel Prize winner Demis Hassabis, is in talks for significant funding at a $40 billion valuation. The lab aims to accelerate the development of new drugs through AI investment. Other companies like China’s DeepSeek, Moonshot, and industry leader OpenAI are also seeking billions in fresh funding to remain competitive in the global AI race. However, some experts warn that excessive spending on AI could create a bubble that might lead to a "far-reaching shock" if it bursts.